Objective: The peroxisome proliferator-activated receptor-g coactivator-1a1 (PGC-1a1) regulates genes involved in energy metabolism. Increasing adipose tissue energy expenditure through PGC-1a1 activation is potentially beneficial for systemic metabolism. Pharmacological PGC-1a1 activators could be valuable tools in the fight against obesity and metabolic disease. Finding such compounds has been challenging partly because PGC-1a1 is a transcriptional coactivator with no known ligand-binding properties. While, PGC-1a1 activation is regulated by several mechanisms, protein stabilization is a crucial limiting step due to its short half-life under unstimulated conditions. Methods: We designed a cell-based high-throughput screening system to identify PGC-1a1 protein stabilizers. Positive hits were tested for their ability to induce endogenous PGC-1a1 protein accumulation and activate target gene expression in brown adipocytes. Select compounds were analyzed for their effects on global gene expression and cellular respiration in adipocytes. Results: Among 7,040 compounds screened, we highlight four small molecules with high activity as measured by: PGC-1a1 protein accumulation, target gene expression, and uncoupled mitochondrial respiration in brown adipocytes. Conclusions: We identify compounds that induce PGC-1a1 protein accumulation and show that this increases uncoupled respiration in brown adipocytes. This screening platform establishes the foundation for a new class of therapeutics with potential use in obesity and associated disorders.
INTRODUCTION
Proteins of the peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) family of transcriptional coactivators regulate genes involved in energy metabolism and are expressed in energydemanding tissues like fat, skeletal muscle, liver, and brain [1] . Interestingly, a single PGC-1a gene can be differently regulated by alternative promoter usage and alternative splicing to generate discrete PGC-1a variants with different biological activities [2e4] . For example, PGC-1a1, the founding member of the family [5] is a strong regulator of mitochondrial biogenesis and oxidative metabolism, whereas PGC1a4 regulates muscle mass and strength [2, 3, 5, 6] . In skeletal muscle, induction of PGC-1a1 promotes a more oxidative phenotype, efficient fuel handling, and increases resistance to fatigue [7] . In addition, skeletal muscle PGC-1a1 activates local kynurenine detoxification, thereby positively impacting on mental health [8, 9] . In the brain, PGC1a1 has been implicated in reactive oxygen species (ROS) detoxification and protection from neurodegenerative disease [10] . However, it is in brown adipose tissue that PGC-1a1 shows the highest expression and has some of its most well-established roles. Initially discovered for its ability to induce mitochondrial biogenesis and adaptive thermogenesis in brown adipocytes, PGC-1a1 has been shown to coordinate the expression of thermogenic genes, of which uncoupling protein 1 (Ucp1) is of central importance [5, 6, 11] . This mechanism is also inducible in white adipose depots, through an adipocyte population called beige, brite, or recruitable (hereon referred to as beige adipocytes) [12e15] . Moreover, PGC-1a1 expression correlates with typical markers of beige-selective genes in human brown adipose tissue [16] . Therefore, elevated PGC-1a1 levels in adipose tissue could have beneficial effects on systemic metabolism, making PGC-1a1 an interesting target in the treatment of obesity and type 2 diabetes [17, 18] . Genetic deletion of PGC-1a1 (knockout) in adipose tissue perturbs the mitochondrial and thermogenic gene programs rendering mice carrying the knockout alleles more sensitive to high-fat dietinduced insulin resistance [19] . In addition, diabetic humans have reduced PGC-1a levels in adipose tissue, which may contribute to the pathogenesis of metabolic disease [20, 21] . For these reasons, there are great therapeutic promises in finding ways to activate PGC-1a1 and its target genes. PGC-1a1 activation can be achieved through several mechanisms including gene expression, protein stabilization, and post-translational modifications. Previous attempts to screen for regulators of PGC-1a1 action have focused on identifying inducers of PGC-1a1 gene transcription (potential activators) or of PGC-1a1 acetylation (potential inhibitors) [22e26] . However, the short protein half-life makes protein stabilization a limiting step in the activation process of PGC-1a1 and downstream target gene transcription [4,27e32] . Indeed, PGC-1a1 levels are tightly controlled by several E3 ubiquitin-ligases that target the protein for ubiquitin-proteasome-mediated degradation [27, 29, 30, 33] . Additionally, it has been suggested that PGC-1a1 is an intrinsically disordered protein, which makes it susceptible to default degradation by the 20S proteasome [34] . Here, we report the development of a cell-based high-throughput screening system that allows for the identification of agents that activate PGC-1a1 by increasing protein stability. Using this system, we were able to identify several small molecule PGC-1a1 activators that are biologically active in brown adipocytes. Treatment of adipocytes with select compounds leads to PGC-1a1 protein accumulation, increased Ucp1 expression, and higher mitochondrial respiration rates.
EXPERIMENTAL PROCEDURES

Plasmids and cell lines
2.1.1. Establishment of the screening cell line To generate a pEGFP-C1-mousePGC-1a1 plasmid (containing a neomycin selection cassette), the cDNA for mouse PGC-1a1 (mPGC1a1) was excised from a previously published pcDNA3.1-Flag-mPGC1a1 plasmid [2] using XhoI and NotI. The pEGFP-C1 was opened with BglII and the cDNA for mouse PGC-1a1 was subsequently blunt-end ligated downstream of EGFP. To efficiently produce EGFP-PGC-1a1 fusion protein the A in the start codon for PGC-1a1 was point mutated to a G (generating valine instead of methionine) using QuickChange II Site-Directed Mutagenesis Kit (Agilent Technologies, #200523). To generate the screening cell line (293-EGFPmPGC-1a1), human embryonic kidney (HEK) 293-T cells were transfected with the pEGFP-C1-mPGC-1a1 plasmid using Lipofectamine Ò 2000 (Thermo Fisher Scientific). Stable cell lines were generated by culturing cells in the presence of 500 mg/ml G418 (also termed Geneticin Ò , Thermo Fisher Scientific, #11811). Single cell-derived colonies were obtained using a dilution protocol. Cells were subsequently cultured according to standard protocols for HEK 293 cells in DMEM high glucose (Gibco, #31966021) containing 10% Fetal Bovine Serum (FBS, Sigmae Aldrich, #F7524) and penicillin/streptomycin (pen/strep) (Gibco, #15140122) in the presence of 500 mg/ml G418. Cells were grown at 37 C in 5% CO 2 .
2.1.2. Brown adipocyte cell line Validation of compound screening was done in an immortalized brown preadipocyte line of mouse origin and was a kind gift from Dr. Bruce Spiegelman (Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA) and has been described previously [35] . Preadipocytes were cultured in DMEM high glucose (Gibco, #31966021) containing 20% FBS (SigmaeAldrich, #F7524), 20 mM Hepes (Gibco, #15630056), and pen/strep (Gibco, #15140122). For differentiation, cells were seeded and grown to confluence in differentiation medium (DMEM high glucose supplemented with 10% FBS, 20 nM insulin, and 1 nM triiodothyronine, T3). Cells were subsequently induced to differentiate with an induction medium (i.e. differentiation medium supplemented with 0.125 mM indomethacin, 0.5 mM dexamethasone and 0.5 mM isobutyl methylxanthine) for 2 days, after which, medium was changed to differentiation medium for 3e4 additional days. Fully differentiated brown adipocytes were exposed to 10 mM of compound or 0.1% DMSO for 8 h. Isoproterenol (10 mM) was included as a positive control (as previously reported [35] ). MG132 treated cells were included to control for general proteasome inhibition. Following treatment, cells were used for cellular respirometry or harvested for isolation of protein and RNA. Cells were grown at 37 C in 5% CO 2 .
High-throughput screening, image acquisition and analysis
The compound library used in this study was a collection of compounds from the Enamine Ltd Drug-Like Set and Pharmacological Diversity Set, which constitutes a total of 28,160 compounds. Compounds in the Drug-Like Set are selected using diversity sorting from the combined file of high-throughput screening and historical collections and strictly conform to rules of Lipinski and Veber [36, 37] , and do not bear undesired reactive functional groups. Compounds from the Pharmacological Diversity Set are particularly recommended for research on new targets because only biologically relevant chemical space has been searched. Moreover, the design is based on the use of predicted pharmacological properties of compounds. Each compound from Enamine collection was profiled by over 3000 activities. Compounds predicted to be toxic are excluded; the others are clustered by their activities. 293-EGFPmPGC-1a1 cells, stably expressing the EGFP-PGC-1a1 fusion protein, were seeded with laminin (L2020, SigmaeAldrich) 0.2 mg/cm 2 in 384-well optical bottom plates (BD Falcon Optilux #353962 plates) using a Multidrop. Prior to the experiment 50 nl of the library compounds were transferred using an ECHO 550 (Labcyte Inc.) acoustic liquid handler to destination plates and stored at À20 C. Twenty-four hours after seeding the cells the compound plates were thawed and 20 ml of cell culture medium was added to the plates using a Multidrop. Compound plates were shaken for 1 h at RT after which 20 ml compound solution was transferred to the cell plate using a PerkinElmer Janus 384 MTD system. Cells were incubated in a final concentration 10 mM of each compound, 0.1% DMSO (¼negative control) or 10 mM of a proteasome inhibitor, MG132 (¼positive control) for 8 h in 37 C, 5% CO 2 . After 8 h treatment, cells were fixed in 4% paraformaldehyde and stained with Hoechst 33342 (nuclear staining). Fluorescence was detected in a fully automated system using Subtracting antimycin A-insensitive OCR (non-mitochondrial respiration) from baseline OCR reveals basal mitochondrial respiration. ATPlinked respiration is represented by oligomycin-sensitive OCR. Oligomycin-insensitive rates represent uncoupled respiration (proton leak), and FCCP rates represent maximal respiratory capacity. Experiments were repeated at least 4 times.
Gene expression analysis
RNA was extracted using Isol RNA lysis reagent (5 PRIME), DNase treated (Invitrogen), and reverse transcribed (Applied Biosystems). Gene expression was measured using Power SYBR Green PCR Master Mix in a Viia 7 Real-Time PCR System (Applied Biosystems) and normalized to hypoxanthine-guanine phosphoribosyltransferase (Hprt). Expression values shown are normalized for Hprt and expressed relative to experimental controls. Primer sequences are listed in Table S1 . 
RESULTS
3.1.
A cell-based screening system for PGC-1a1 stabilizers PGC-1a1 has been shown to have a short half-life, which is conserved even upon ectopic expression of the protein in different cells [4, 30] .
Using HEK 293 cells, we determined that adding a N-terminal tag (either Flag or EGFP, Enhanced Green Fluorescent Protein) to PGC-1a1 does not significantly affect protein stability (Figure 1AeC ). However, to achieve robust expression of the EGFP-PGC-1a1 chimera in HEK 293 cells, it was important to mutate the start codon of PGC-1a1 (Supplementary Figure 1) to prevent expression of the untagged protein. We next generated a HEK 293 stable cell line that expresses EGFP-mPGC-1a1 under a CMV promoter (293-EGFPmPGC-1a1 cell line), at levels that are efficiently degraded by the endogenous protein degradation machinery, but still robustly accumulate upon inhibition of the ubiquitin-proteasome system. Indeed, treatment of the 293-EGFPmPGC-1a1 stable cell line with a proteasome inhibitor (MG132) induced accumulation of the EGFP-PGC-1a1 fusion protein, detectable by both immunoblotting ( Figure 1D ) and by fluorescence microscopy ( Figure 1E ). To further validate that MG132-induced EGFP-PGC-1a1 accumulation was due to protein stabilization, and not to effects on the CMV promoter (i.e. increased transcription), we analyzed expression of the EGFP-PGC-1a1 transcript by targeted qRT-PCR using specific probes ( Figure 1F ). The small increase in ectopic PGC-1a1 gene expression (measured by both isoform specific and unspecific primers) would not account for the robust stabilization of PGC-1a1 protein ( Figure 1F ,D).
Identification of small molecule PGC-1a1 stabilizers/activators
To identify compounds that stabilize PGC-1a1 protein and activate its target genes, we adapted the 293-EGFPmPGC-1a1 cells to grow in 384-well optical-bottom plates, which are suitable for automated cell plating, compound treatment, and fluorescence microscope analysis. For the selection of compounds to screen, we chose a subset of the drug-like and pharmacological diversity sets from Enamine Ltd, which consists of approximately 7040 small molecule compounds (approximately 25% of the library). Cells were then exposed to compounds (or controls) for 8 h to minimize any unspecific activation of the CMV promoter that drives EGFP-PGC-1a1 expression. Changes in fluorescence intensity and localization were detected and quantified using a fully automated high content microscopy system. The well median of integrated intensity measured with whole cell boundary (Cell sum intensity median per well) was used as a preferred parameter þ nuclear intensity, giving reasonable Z 0 factor values (Z value) and consistent assay window, to calculate percent activation. The cut-off of 57%, equal to the mean of % activation þ 2 * standard deviation (SD) was applied to identify active compounds which generated 114 primary hits ( Figure 2A ). Remaining compounds were classified according to the subcellular localization of the EGFP-PGC-1a1 signal (whole cell, nuclear, cytoplasmic or spots) ( Figure 2B ). Analysis of the screening output data by similarity in cellular distribution of the EGFP-PGC-1a1 signal (cell sum, nucleus, cytoplasm or punctate) induced by the screening compounds generated 7 clusters ( Figure 2C ). Clusters included compounds that induced a strong signal in all cellular compartments (clusters 4 and 6) including a nuclear punctate distribution (cluster 7), to compounds that induced a modest subcellular localization (clusters 2, 3 and 5) and weak induction (cluster 1).
Chemical structure analysis
To determine if we could gain any mechanistic insight about the selected compounds or, for example, predict potential toxicity, we compared the chemical structures of our primary hits with the structures of previously known compounds in Bioactivity assay data available through PubChem. Among the 114 primary hits we were able to identify 4 structures tested in previous bioactivity assays and 2 of them (AM72 and AM90) were declared as active but not good hits in their respective assay. However, these 2 compounds were not selected as candidates in our validation assays based on the gene expression and protein stabilization results. Compound structures were also searched for PAINS patterns. The chemical structures of any detected PAINS were then individually analyzed to further evaluate their potential usefulness in further validation process.
3.4. Primary and secondary validation of PGC-1a1 activators using brown adipocytes From the primary 114 hits we selected 79 compounds with the highest EGFP-mPGC-1a1 intensities and representing different EGFP-mPGC1a1 distribution patterns (nucleus, cytosolic and spots) for further validation assays. Primary validation of the selected 79 compounds was performed using a mouse brown preadipocyte cell line, which can be differentiated to mature brown adipocytes with endogenous PGC1a1 expression. Differentiated brown adipocytes are responsive to beta-adrenergic stimulation (using, for example, isoproterenol) to activate PGC-1a1-driven gene networks [35] . Fully differentiated brown adipocytes were exposed to each compound (10 mM final concentration), or DMSO (negative control), or 10 mM isoproterenol (positive control) for 8 h. MG132 was included to compare compound effects to a general proteasome inhibitor. Primary compound validation was then performed by quantitative real-time PCR (qRT-PCR) analysis of PGC-1a1 target gene activation ( Figure 3A) . To this end, we determined the expression of known PGC-1a1 target genes involved in browning/thermogenesis, mitochondrial biogenesis, oxidative phosphorylation, and anti-oxidant defenses [5, 6, 10, 38, 39] . This approach was used to exclude compounds with general toxic effects for the cells, including general proteasome inhibitors, which could impact PGC1a1-induced gene expression and biological effects [40] . Among the genes we evaluated, Ucp1 showed the highest induction after compound treatment ( Figure 3A) . Among all the validated compounds, 19 compounds (approximately 23% of the selected compounds) induced Ucp1 expression by at least 2-fold with the highest observed induction at 15-fold for compound AM80 ( Figure 3A) . Treatment of brown adipocytes with AM31, AM73, AM79, and AM80 increased Ucp1 12-to 15-fold, while for AM89 the increase was 5-fold ( Figure 3B ). In comparison, the positive control isoproterenol induced Ucp1 55-fold. Treatment of brown adipocytes with the general proteasome inhibitor MG132 resulted in a repression of gene expression for most PGC-1a1 target genes ( Figure 3B ), despite the modest increase in total PGC-1a mRNA expression. AM31, AM73, AM79, and AM80 also induced Cidea expression ( Figure 3B ). Of the tested compounds, AM80 showed the broadest activity on increasing PGC-1a1 target gene expression in brown adipocytes. Secondary hit validation was performed by testing each compound for its ability to stabilize endogenous PGC-1a1 protein in brown adipocytes ( Figure 3C and Supplementary Figures 3e6) . To determine the maximal PGC-1a1 protein accumulation in brown adipocytes, MG132 was used to block proteasome degradation, and isoproterenol was used as a biologically active positive control. As expected PGC-1a1 stabilization by MG132 treatment was higher than stabilization following treatment with isoproterenol ( Figure 3C ). Of the tested compounds, 45 induced PGC-1a1 protein accumulation as determined by immunoblotting using whole cell extracts from mature brown adipocytes treated with each compound, and anti-PGC-1a antibodies ( Figure 3C and Supplementary Figures 3e6) . In summary, 22 of the validated compounds induced Ucp1 expression (>2-fold) and 17 compounds induced both Ucp1 expression and PGC-1a1-protein accumulation (Supplementary Figures 3e6) . Of these 17 compounds, we selected five that stabilized PGC-1a1 protein and induced a robust increase in Ucp1 expression (>5-fold). The selected compounds were AM31, AM73, AM79, AM80, and AM89. In fact, when compared to the positive and negative controls, these compounds were able to stabilize endogenous PGC-1a1 to levels comparable to cold-induced brown adipose tissue [2, 41] . Screening images, EGFP-PGC-1a1 intensities, Enamine IDs and chemical structures for the five selected compounds are shown in Figure 4 A-C. High-resolution images for the selected compounds are shown in Supplementary Figures S7e11.
PGC-1a1 activators increase mitochondrial respiration in brown adipocytes
We next measured cellular respiration in brown fat cells treated with AM31, AM73, AM79, AM80, or AM89. In line with the observed increases in Ucp1 expression ( Figure 3C ), we observed an increase in basal mitochondrial respiration (corrected for non-mitochondrial respiration) for all compounds except AM89 (Figure 5AeF ). This increase in basal respiration was maintained even after addition of oligomycin (an inhibitor of ATP synthase), indicating an increase in uncoupled respiration rather than ATP turnover. Only compound AM80 showed a small increased maximal respiration (after addition of FCCP).
Global gene expression analysis of adipocytes treated with PGC-1a1 activators highlights effects on energy metabolism
Since PGC-1a1 activation can be achieved through several pathways we decided to explore the mechanisms of action for select compounds. Consequently, we performed a global analysis of gene expression in brown adipocytes treated with AM73 or AM80 for 8 h (data deposited at Gene Expression Omnibus under accession number GSE107630). We selected these two compounds based on their overall profile as PGC-1a1 activators. This included the EGFP-PGC-1a1 intensities from the screening cell line (Figure 4B ), the ability to stabilize endogenous PGC-1a1, and to activate PGC-1a1 target genes in brown adipocytes (Figure 3AeC ). The general distribution of target gene expression for AM73 and AM80 in brown adipocytes is represented in a heat map and in volcano plots (Figure 6AeC) . In this analysis, we identified 1380 genes regulated by AM73 and 4913 regulated by AM80, of which 507 genes were common to both compounds ( Figure 6D ). To further analyze these results, we looked at the biological processes, molecular functions, and KEGG pathways regulated by either compound alone or by both (Figure 6EeG ). Interestingly, AM73-regulated pathways comprised typical PGC-1a1-controlled pathways such as hypoxia, brown fat cell differentiation, carbohydrate metabolism, and insulin signaling ( Figure 6E ). These pathways were also shared between AM73 and AM80 ( Figure 6G ). To further analyze the transcriptional networks regulating the genes differentially expressed upon AM73/ AM80 treatment, we performed a DiRE (distant regulatory elements of co-regulated genes) analysis. In line with our observations, and further supporting a functional activation of PGC-1a1, we found that regulatory regions surrounding co-regulated genes tended to contain transcription factor binding sites for many previously known PGC-1a1 binding partners, including CCAAT-enhancer-binding proteins (C/EBP), hepatocyte nuclear factor (HNF), X-box binding protein 1 (XBP1), peroxisome proliferator-activated receptor a (PPARa), nuclear respiratory factors 2 (NRF2), myocyte enhancer factor 2 (MEF2), sterol regulatory element-binding protein 1 (SREBP1) (Figure 6HeI ). Complete lists of regulatory elements as predicted by DiRE are found in Supplementary Tables 2 and 3 .
To compare the gene expression changes following AM73/AM80 treatment with those observed for other known browning agents, we used publicly available data from cAMP-treated brown adipocytes (GEO GSE5041 [35] obtained with the same cells used in this study). Cyclic AMP is a second messenger of beta-adrenergic receptor stimulation, a classical inducer of thermogenic programs in brown fat cells [42] . Among 6734 genes regulated by cAMP, 433 were co-regulated by AM73, corresponding to approximately 31% of AM73 targets ( Figure 7A ). AM80 and cAMP shared 39% of their target genes (Supplementary Figure 12) . The pathways regulated by both cAMP and AM73 were further divided ( Figure 7A ) as induced by both cAMP and AM73 (top right), reduced by both cAMP and AM73 (bottom left), induced by cAMP and reduced by AM73 (top left) or reduced by cAMP and induced by AM73 (bottom right). For example, blood vessel development was induced by both cAMP and AM73. Interestingly, oxidation/reduction and brown fat cell differentiation were among the pathways regulated by AM73 alone (Figure 7AeB) . A similar analysis was performed for cAMP and AM80, and is shown in Supplementary  Figure S12 .
DISCUSSION
PGC-1a1 exerts its role as a transcriptional coactivator by binding to a variety of transcription factors (such as nuclear receptors) as well as to other transcription-associated protein complexes such as the Mediator, histone-modifying enzymes, and the splicing machinery [43e45]. PGC-1a1 does not contain a DNA-binding domain but works as a docking platform for other proteins to promote assembly of the necessary gene regulatory protein complexes [1] . In many cases, the binding partners for PGC-1a1 are expressed in the target cells leaving PGC-1a1 as the limiting factor for target gene activation [19, 35] . The reason for that is the fact that activation of PGC-1a1 is a highly regulated process, that relies heavily on diverting the protein from ubiquitin-proteasome-mediated degradation. In this context, and to explore the possibility of using an unbiased approach to identify new strategies to target PGC-1a1, we designed a cell-based screening system that targets PGC-1a1 activity through increased protein stability. Other previously published PGC-1a1 screening systems have aimed at finding transcriptional activators or inducers of PGC-1a1-acetylation that could lead to PGC-1a1 inhibition in the liver [22e25]. Using our screening platform, we tested 7040 small molecule compounds and identified 114 primary hits (representing a 1.51% hit rate). Based on the EGFP-PGC-1a1 signal intensity and subcellular distribution pattern we selected 79 compounds for validation assays. Of 79 validated compounds 17 compounds were confirmed true positive hits by PGC-1a1 protein accumulation and target gene activation in a biologically relevant system. To obtain as much information as possible from the screening results, we decided to use more relaxed criteria (i.e. mean þ 2 * stdev instead of mean þ 3 * stdev, commonly used in high throughput screening) for selecting compounds to be tested in the hit A. validation stage. However, to screen larger compound sets with this system, elimination of false positives could be further enhanced by a combination of higher cut-off limit (e.g. mean þ 3 * stdev) and another round of secondary screening in the same screening cell line. Nevertheless, our platform proved to be stable and reproducible and would easily be transferable to a larger format. The validation process relied primarily on the analysis of PGC-1a1 target genes involved in non-shivering thermogenesis, using a brown adipocyte cell line that expresses PGC-1a1 endogenously [35] . This was done to preclude any compounds that although stabilizing PGC1a1 did not lead to target gene activation (due to, for example, cell toxicity). With this approach, we validated 79 compounds and showed that 45 compounds stabilized PGC-1a1, 17 of which also induced Ucp1 expression by at least 2-fold. One major concern of screening for PGC-1a1 protein stabilizers is identifying candidates that affect general protein turnover, such as proteasome inhibitors. To address this, we performed hit validation in two steps looking at both PGC-1a1 protein stability and target gene activation. Using this approach, we were able to monitor the biological activity of PGC-1a1 thereby increasing the chances of identifying Original Article 38 compounds that target PGC-1a1-related pathways. Moreover, determining PGC-1a1 target gene expression in brown adipocytes treated with the proteasome inhibitor MG132 resulted in reduced expression for most genes we analyzed. This gene expression profile is clearly different from the ones we determined for our selected compounds, indicating that none of the tested compounds are general proteasome inhibitors. One additional concern is that our PGC-1a1 activators may inhibit E3 ubiquitin-ligases that are not specific to PGC-1a1. Although such compounds could still be usable, they could also affect the stability of other proteins with possible unwanted effects. However, the overlap between PGC-1a1 stabilizers and inducers of target gene expression was not complete. For example, several compounds stabilized PGC-1a1 protein but only induced small (<1.5 fold) or no changes in the target gene expression measured in our validation assays. It is possible that these compounds induced stabilization of PGC-1a1 protein by post-translational modifications (PTMs) that target PGC-1a1 to other, yet unknown target genes. In contrast only 5 compounds induced Ucp1 expression without affecting PGC1a1 protein stability. It is likely that these compounds induced Ucp1 expression through PGC-1a1-independent mechanisms, or that they induce PTMs that lead to more efficient target gene activation without increasing total PGC-1a1 protein.
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Along with the changes in gene expression and PGC-1a1 protein accumulation in brown adipocytes, compound AM31, AM73, AM79, and AM80 increased basal respiration measured as oxygen consumption rate. This change was maintained after blocking ATP synthase (following oligomycin addition), suggesting that the effect on basal mitochondrial respiration was primarily due to increased uncoupled respiration, likely related to the increase in Ucp1 expression. The maximal respiratory capacity was slightly increased with compound AM80, which could indicate more mitochondria and/or mitochondrial protein.
Since this chemical compound library subset was selected for structural diversity, thus enhancing the chances of targeting different components of the PGC-1a1 degradation pathway, very little information is available for each hit. We next performed global gene expression analysis of brown adipocytes treated with either AM73 or AM80 (selected for their EGFP intensities and induction of Ucp1 expression) in order to (a) better understand the mechanisms of PGC1a1 stabilization, and (b) compare the browning/thermogenic signature of these compounds with other known browning agents. By looking at the microarray data and the genes highlighted in the analysis, we can conclude that AM73, and to some extent AM80, regulates pathways involved in brown fat differentiation, response to hypoxia, and carbohydrate metabolism. In our prediction of transcription factors controlling the gene expression changes, we confirmed several known PGC-1a1-binding partners, including C/EBP, XBP1, HNF, PPARa, NRF2, MEF2, and SREBP1. All of these transcription factors are expressed in adipocytes and it is likely that PGC1a1 is the limiting factor controlling the transcription of their respective target genes. In line with this, PGC-1a1 ablation in either adipose tissue or adipocytes doesn't affect the expression levels of adipogenesis-regulating transcription factors like PPARg and C/EBPa [19, 35] . However, the absence of PGC-1a1 affects mainly the induction of genes such as Ucp1, Cytc, and Esrra by, for example, badrenergic stimuli (e.g. cAMP). Interestingly, when compared to each other or to cAMP, AM73 and AM80 seem to also have specific gene signatures. This could indicate distinct PGC-1a1 activating mechanisms not related to the classical cAMP-induced pathways. For example, oxidation/reduction and brown fat cell differentiation were pathways regulated by AM73 alone. These pathways included typical browning genes, e. g. Ucp1, Prdm16, and Ebf2, as well as Kdm3a (also termed Jmjd1a or Jhdm2a), an H3K9-specific demethylase that regulates Ppara and Ucp1 expression [46] . Also induced by AM73 and included in the oxidation/reduction pathway are Kdm4b (lysine demethylase 4B) and Tet2 (tet methylcytosine dioxygenase 2). Kdm4b and Tet2 are both involved in adipogenesis by regulation of C/EBPb activity and the PPARg locus, respectively. Overall, the global gene expression profile for AM73 indicated a regulation of pathways involved in browning and thermogenesis distinct from b-adrenergic signaling.
Together with the effect of AM73 on Ucp1 expression and uncoupled respiration, the global gene expression changes suggested activation of thermogenic processes in brown adipocytes. Previous studies show that overexpression of human PGC-1a1 induces brown fat features in human white adipocyte [11] . It is therefore tempting to speculate that AM73 could also be used to activate thermogenic processes in white adipocytes. Moreover, it is conceivable that co-treatment with classical browning factors, e.g. low-dose isoproterenol, could accelerate the thermogenic effects of the compounds in white adipocytes. Finally, a careful titration of each compound, in combination or not with other browning agents, could potentially result in stronger effects than the ones we report here. The exact mechanisms of action for the compounds are still unclear. Several reports have shown that PGC-1a1 stability can be controlled by PTMs such as phosphorylation [47e52], acetylation [53] and deacetylation [54, 55] , methylation [56] , SUMOylation [57] or OGlcNAcylation [28] . Many of these PTMs impact the interaction with binding partners or increase the association of PGC-1a1 with E3 ligases, eg Skp1/Cullin/F-box-cell division control 4 (SCF Cdc4 ) and Ring-finger-containing protein 34 (RNF34), thereby targeting the protein for proteasomal degradation [27, 29] . PGC-1a1 stability is also proposed to be governed by the N-terminal pathway [30] . Yet, our Nterminal Flag-and EGFP-PGC-1a1 fusion proteins did not significantly differ in their stability compared to previous observations [30, 58] , suggesting that other proteasome targeting pathways might be more dominant. Additionally, the compounds could act on the protein itself. PGC-1a1 has been suggested to be an intrinsically disordered protein. These are proteins that lack a stable three-dimensional structure and rapidly cycle between different conformations [59] . Interaction with small compounds could theoretically stabilize a conformation making the protein more stable and less susceptible for degradation [60] . One concern with systemic PGC-1a1 activation with a small molecule such as the compounds that we identify in this study is that higher PGC-1a1 activity in the liver could induce glucose output, an undesirable effect in an obesity or type 2 diabetes setting. However, the specificity of PGC-1a1 action in different tissues critically depends on the transcription factors present in those cells and on the posttranslational status of PGC-1a1 itself. For example, in hepatocytes PGC-1a1 modification through phosphorylation by S6kinase attenuates its ability to enhance gluconeogenic gene transcription but does not interfere with the PGC-1a1-driven activation of mitochondrial and fatty acid oxidation pathways [50] . Moreover, AMPK activation in skeletal muscle drives the phosphorylation and subsequent activation of PGC-1a1 whereas AMPK activation in hepatocytes blocks fastinginduced PGC-1a1 trough TORC2 and CREB [49] . These tissuespecific regulatory pathways clearly demonstrate that the outcome of PGC-1a1 activation will depend not only on the stability of the protein but also on the post-translational modifications of PGC-1a1 itself as well as the presence of specific transcription factors. Although this complicates the prediction of activating PGC-1a1 systemically, it also highlights the possibility of activating a specific gene network (e.g. mitochondrial genes and fatty acid oxidation) while leaving other pathways unaffected (e.g. gluconeogenesis). In addition, further development of these compounds through medical chemistry could avoid targeting the liver, and therefore reduce any unwanted effects on hepatic glucose output. In addition to metabolic disease, PGC-1a1 activation could potentially be useful in other diseases as well. These include neurodegenerative disorders, mood, and especially muscle atrophy, for which there are still no effective treatments [7, 8, 61] . Muscle-specific expression of PGC-1a1 leads to the enrichment of type I fibers in transgenic mice and to a more oxidative phenotype [7] that protects these muscles from atrophy [61] . PGC-1a1 also drives and maintains the function of synapses in hippocampal dendritic spines [62] and neuromuscular junctions [63] . Furthermore, higher expression of PGC-1a1 in muscle protects the brain from high levels of kynurenine, a tryptophan metabolite that induced stress responses in the brain and has been linked to depression [8] . In summary, by developing a platform to screen for inducers of PGC1a1 protein accumulation and activity, we have identified four compounds with the ability to stabilize PGC-1a1 protein, activate Ucp1 expression and induce uncoupled respiration in brown adipocytes. The specific platform development allows for easy adaptation to other screens, such as siRNA or other biologicals. This study sets the foundation for a novel generation of therapeutics based on the activation of PGC-1a1 that could be of use in metabolic disease and other pathologies.
